Hepatic SREBP-2 and cholesterol biosynthesis are regulated by FoxO3 and Sirt6

Journal of Lipid Research

Volumn 54, Issue 10, 2013, Pages 2745-2753

  Tao, Rongya ^a   Xiong, Xiwen ^a   DePinho, Ronald A ^b   Deng, Chu Xia ^c   Dong, X Charlie ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Epigenetics; Forkhead box O3 transcription factor; Gene regulation; Histone acetylation; Sirtuin 6; Sterol regulatory element binding protein 2; Transcription

Indexed keywords

CHOLESTEROL; HISTONE H3; LYSINE; MESSENGER RNA; SIRTUIN 6; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRANSCRIPTION FACTOR FKHRL1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DOWN REGULATION; ENZYME DEFICIENCY; FOXO3 GENE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE TARGETING; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; IN VIVO STUDY; LIVER METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS REGULATION; REGULATOR GENE; SIRT6 GENE; SREBP2 GENE;

EPIGENETICS; FORKHEAD BOX O3 TRANSCRIPTION FACTOR; GENE REGULATION; HISTONE ACETYLATION; SIRTUIN 6; STEROL-REGULATORY ELEMENT BINDING PROTEIN 2; TRANSCRIPTION;

ACETYLATION; ANIMALS; BASE SEQUENCE; CHOLESTEROL; EPIGENESIS, GENETIC; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; GENE KNOCKOUT TECHNIQUES; HEK293 CELLS; HISTONES; HOMEOSTASIS; HUMANS; HYPERCHOLESTEROLEMIA; LIVER; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; PROMOTER REGIONS, GENETIC; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIRTUINS; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

EID: 84884134120     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M039339     Document Type: Article

References (69)

1. Maxfield, F. R., and I. Tabas. 2005. Role of cholesterol and lipid organization in disease. Nature. 438: 612-621.
2. deGoma, E. M., J. W. Knowles, F. Angeli, M. J. Budoff, and D. J. Rader. 2012. The evolution and refinement of traditional risk factors for cardiovascular disease. Cardiol. Rev. 20: 118-129.
3. Sato, R. 2010. Sterol metabolism and SREBP activation. Arch. Biochem. Biophys. 501: 177-181.
4. Horton, J. D., J. L. Goldstein, and M. S. Brown. 2002. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109: 1125-1131.
5. Shao, W., and P. J. Espenshade. 2012. Expanding roles for SREBP in metabolism. Cell Metab. 16: 414-419.
6. Jeon, T. I., and T. F. Osborne. 2012. SREBPs: metabolic integrators in physiology and metabolism. Trends Endocrinol. Metab. 23: 65-72.
7. Biddinger, S. B., A. Hernandez-Ono, C. Rask-Madsen, J. T. Haas, J. O. Aleman, R. Suzuki, E. F. Scapa, C. Agarwal, M. C. Carey, G. Stephanopoulos, et al. 2008. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab. 7: 125-134.
8. Van Rooyen, D. M., and G. C. Farrell. 2011. SREBP-2: a link between insulin resistance, hepatic cholesterol, and inflammation in NASH. J. Gastroenterol. Hepatol. 26: 789-792.
9. Biddinger, S. B., J. T. Haas, B. B. Yu, O. Bezy, E. Jing, W. Zhang, T. G. Unterman, M. C. Carey, and C. R. Kahn. 2008. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat. Med. 14: 778-782.
10. Calkin, A. C., and P. Tontonoz. 2012. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat. Rev. Mol. Cell Biol. 13: 213-224.
11. Wagner, M., G. Zollner, and M. Trauner. 2011. Nuclear receptors in liver disease. Hepatology. 53: 1023-1034.
12. Goedeke, L., and C. Fernandez-Hernando. 2012. Regulation of cholesterol homeostasis. Cell. Mol. Life Sci. 69: 915-930.
13. Haeusler, R. A., S. Han, and D. Accili. 2010. Hepatic FoxO1 ablation exacerbates lipid abnormalities during hyperglycemia. J. Biol. Chem. 285: 26861-26868.
14. Zhang, K., L. Li, Y. Qi, X. Zhu, B. Gan, R. A. DePinho, T. Averitt, and S. Guo. 2012. Hepatic suppression of Foxo1 and Foxo3 causes hypoglycemia and hyperlipidemia in mice. Endocrinology. 153: 631-646.
15. Zhang, W., S. Patil, B. Chauhan, S. Guo, D. R. Powell, J. Le, A. Klotsas, R. Matika, X. Xiao, R. Franks, et al. 2006. FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. J. Biol. Chem. 281: 10105-10117.
16. Liu, Z., M. D. Rudd, I. Hernandez-Gonzalez, I. Gonzalez-Robayna, H. Y. Fan, A. J. Zeleznik, and J. S. Richards. 2009. FSH and FOXO1 regulate genes in the sterol/steroid and lipid biosynthetic pathways in granulosa cells. Mol. Endocrinol. 23: 649-661.
17. Zhu, J., K. Mounzih, E. F. Chehab, N. Mitro, E. Saez, and F. F. Chehab. 2010. Effects of FoxO4 overexpression on cholesterol biosynthesis, triacylglycerol accumulation, and glucose uptake. J. Lipid Res. 51: 1312-1324.
18. Li, X., S. Zhang, G. Blander, J. G. Tse, M. Krieger, and L. Guarente. 2007. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol. Cell. 28: 91-106.
19. Kemper, J. K., Z. Xiao, B. Ponugoti, J. Miao, S. Fang, D. Kanamaluru, S. Tsang, S. Y. Wu, C. M. Chiang, and T. D. Veenstra. 2009. FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. Cell Metab. 10: 392-404.
20. Walker, A. K., F. Yang, K. Jiang, J. Y. Ji, J. L. Watts, A. Purushotham, O. Boss, M. L. Hirsch, S. Ribich, J. J. Smith, et al. 2010. Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP. Genes Dev. 24: 1403-1417.
21. Ponugoti, B., D. H. Kim, Z. Xiao, Z. Smith, J. Miao, M. Zang, S. Y. Wu, C. M. Chiang, T. D. Veenstra, and J. K. Kemper. 2010. SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J. Biol. Chem. 285: 33959-33970.
22. Kaidi, A., B. T. Weinert, C. Choudhary, and S. P. Jackson. 2010. Human SIRT6 promotes DNA end resection through CtIP deacetylation. Science. 329: 1348-1353.
23. Mao, Z., C. Hine, X. Tian, M. Van Meter, M. Au, A. Vaidya, A. Seluanov, and V. Gorbunova. 2011. SIRT6 promotes DNA repair under stress by activating PARP1. Science. 332: 1443-1446.
24. Mao, Z., X. Tian, M. Van Meter, Z. Ke, V. Gorbunova, and A. Seluanov. 2012. Sirtuin 6 (SIRT6) rescues the decline of homologous recombination repair during replicative senescence. Proc. Natl. Acad. Sci. USA. 109: 11800-11805.
25. McCord, R. A., E. Michishita, T. Hong, E. Berber, L. D. Boxer, R. Kusumoto, S. Guan, X. Shi, O. Gozani, A. L. Burlingame, et al. 2009. SIRT6 stabilizes DNA-dependent protein kinase at chromatin for DNA double-strand break repair. Aging (Albany NY). 1: 109-121.
26. Michishita, E., R. A. McCord, E. Berber, M. Kioi, H. Padilla-Nash, M. Damian, P. Cheung, R. Kusumoto, T. L. Kawahara, J. C. Barrett, et al. 2008. SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature. 452: 492-496.
27. Michishita, E., R. A. McCord, L. D. Boxer, M. F. Barber, T. Hong, O. Gozani, and K. F. Chua. 2009. Cell cycle-dependent deacetylation of telomeric histone H3 lysine K56 by human SIRT6. Cell Cycle. 8: 2664-2666.
28. Mostoslavsky, R., K. F. Chua, D. B. Lombard, W. W. Pang, M. R. Fischer, L. Gellon, P. Liu, G. Mostoslavsky, S. Franco, M. M. Murphy, et al. 2006. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell. 124: 315-329.
29. Yang, B., B. M. Zwaans, M. Eckersdorff, and D. B. Lombard. 2009. The sirtuin SIRT6 deacetylates H3 K56Ac in vivo to promote genomic stability. Cell Cycle. 8: 2662-2663.
30. Min, L., Y. Ji, L. Bakiri, Z. Qiu, J. Cen, X. Chen, L. Chen, H. Scheuch, H. Zheng, L. Qin, et al. 2012. Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat. Cell Biol. 14: 1203-1211.
31. Minagawa, S., J. Araya, T. Numata, S. Nojiri, H. Hara, Y. Yumino, M. Kawaishi, M. Odaka, T. Morikawa, S. L. Nishimura, et al. 2011. Accelerated epithelial cell senescence in IPF and the inhibitory role of SIRT6 in TGF-beta-induced senescence of human bronchial epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 300: L391 - L401.
32. Van Meter, M., Z. Mao, V. Gorbunova, and A. Seluanov. 2011. SIRT6 overexpression induces massive apoptosis in cancer cells but not in normal cells. Cell Cycle. 10: 3153-3158.
33. Bauer, I., A. Grozio, D. Lasigliè, G. Basile, L. Sturla, M. Magnone, G. Sociali, D. Soncini, I. Caffa, A. Poggi, et al. 2012. The NAD+- dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses. J. Biol. Chem. 287: 40924-40937.
34. Grimley, R., O. Polyakova, J. Vamathevan, J. McKenary, B. Hayes, C. Patel, J. Smith, A. Bridges, A. Fosberry, A. Bhardwaja, et al. 2012. Over expression of wild type or a catalytically dead mutant of Sirtuin 6 does not influence NFκB responses. PLoS ONE. 7: e39847.
35. Kawahara, T. L., E. Michishita, A. S. Adler, M. Damian, E. Berber, M. Lin, R. A. McCord, K. C. Ongaigui, L. D. Boxer, H. Y. Chang, et al. 2009. SIRT6 links histone H3 lysine 9 deacetylation to NFkappaB- dependent gene expression and organismal life span. Cell. 136: 62-74.
36. Kawahara, T. L., N. A. Rapicavoli, A. R. Wu, K. Qu, S. R. Quake, and H. Y. Chang. 2011. Dynamic chromatin localization of Sirt6 shapes stress- and aging-related transcriptional networks. PLoS Genet. 7: e1002153.
37. Van Gool, F., M. Galli, C. Gueydan, V. Kruys, P. P. Prevot, A. Bedalov, R. Mostoslavsky, F. W. Alt, T. De Smedt, and O. Leo. 2009. Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner. Nat. Med. 15: 206-210.
38. Xiao, C., R. H. Wang, T. J. Lahusen, O. Park, A. Bertola, T. Maruyama, D. Reynolds, Q. Chen, X. Xu, H. A. Young, et al. 2012. Progression of chronic liver inflammation and fibrosis driven by activation of c-JUN signaling in Sirt6 mutant mice. J. Biol. Chem. 287: 41903-41913.
39. Cai, Y., S. S. Yu, S. R. Chen, R. B. Pi, S. Gao, H. Li, J. T. Ye, and P. Q. Liu. 2012. Nmnat2 protects cardiomyocytes from hypertrophy via activation of SIRT6. FEBS Lett. 586: 866-874.
40. Sundaresan, N. R., P. Vasudevan, L. Zhong, G. Kim, S. Samant, V. Parekh, V. B. Pillai, P. V. Ravindra, M. Gupta, V. Jeevanandam, et al. 2012. The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun. Nat. Med. 18: 1643-1650.
41. Yu, S. S., Y. Cai, J. T. Ye, R. B. Pi, S. R. Chen, P. Q. Liu, X. Y. Shen, and Y. Ji. 2013. Sirtuin 6 protects cardiomyocytes from hypertrophy in vitro via inhibition of NF-κB-dependent transcriptional activity. Br. J. Pharmacol. 168: 117-128.
42. Chiang, W. C., D. X. Tishkoff, B. Yang, J. Wilson-Grady, X. Yu, T. Mazer, M. Eckersdorff, S. P. Gygi, D. B. Lombard, and A. L. Hsu. 2012. C. elegans SIRT6/7 homolog SIR-2.4 promotes DAF-16 relocalization and function during stress. PLoS Genet. 8: e1002948.
43. Kanfi, Y., S. Naiman, G. Amir, V. Peshti, G. Zinman, L. Nahum, Z. Bar-Joseph, and H. Y. Cohen. 2012. The sirtuin SIRT6 regulates lifespan in male mice. Nature. 483: 218-221.
44. Kanfi, Y., V. Peshti, R. Gil, S. Naiman, L. Nahum, E. Levin, N. Kronfeld-Schor, and H. Y. Cohen. 2010. SIRT6 protects against pathological damage caused by diet-induced obesity. Aging Cell. 9: 162-173.
45. Kim, H. S., C. Xiao, R. H. Wang, T. Lahusen, X. Xu, A. Vassilopoulos, G. Vazquez-Ortiz, W. I. Jeong, O. Park, S. H. Ki, et al. 2010. Hepaticspecific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis. Cell Metab. 12: 224-236.
46. Schwer, B., B. Schumacher, D. B. Lombard, C. Xiao, M. V. Kurtev, J. Gao, J. I. Schneider, H. Chai, R. T. Bronson, L. H. Tsai, et al. 2010. Neural sirtuin 6 (Sirt6) ablation attenuates somatic growth and causes obesity. Proc. Natl. Acad. Sci. USA. 107: 21790-21794.
47. Xiao, C., H. S. Kim, T. Lahusen, R. H. Wang, X. Xu, O. Gavrilova, W. Jou, D. Gius, and C. X. Deng. 2010. SIRT6 deficiency results in severe hypoglycemia by enhancing both basal and insulin-stimulated glucose uptake in mice. J. Biol. Chem. 285: 36776-36784.
48. Zhong, L., A. D'Urso, D. Toiber, C. Sebastian, R. E. Henry, D. D. Vadysirisack, A. Guimaraes, B. Marinelli, J. D. Wikstrom, T. Nir, et al. 2010. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell. 140: 280-293.
49. Yang, S. J., J. M. Choi, S. W. Chae, W. J. Kim, S. E. Park, E. J. Rhee, W. Y. Lee, K. W. Oh, S. W. Park, S. W. Kim, et al. 2011. Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone increases sirt6 expression and ameliorates hepatic steatosis in rats. PLoS ONE. 6: e17057.
50. Dominy, J. E., Jr ., Y. Lee, M. P. Jedrychowski, H. Chim, M. J. Jurczak, J. P. Camporez, H. B. Ruan, J. Feldman, K. Pierce, R. Mostoslavsky, et al. 2012. The deacetylase Sirt6 activates the acetyltransferase GCN5 and suppresses hepatic gluconeogenesis. Mol. Cell. 48: 900-913.
51. Liu, T. F., V. T. Vachharajani, B. K. Yoza, and C. E. McCall. 2012. NAD+-dependent sirtuin 1 and 6 proteins coordinate a switch from glucose to fatty acid oxidation during the acute inflammatory response. J. Biol. Chem. 287: 25758-25769.
52. Liszt, G., E. Ford, M. Kurtev, and L. Guarente. 2005. Mouse Sir2 homolog SIRT6 is a nuclear ADP-ribosyltransferase. J. Biol. Chem. 280: 21313-21320.
53. Jiang, H., S. Khan, Y. Wang, G. Charron, B. He, C. Sebastian, J. Du, R. Kim, E. Ge, R. Mostoslavsky, et al. 2013. SIRT6 regulates TNFalpha secretion through hydrolysis of long-chain fatty acyl lysine. Nature. 496: 110-113.
54. Tao, R., D. Wei, H. Gao, Y. Liu, R. A. DePinho, and X. C. Dong. 2011. Hepatic FoxOs regulate lipid metabolism via modulation of expression of the nicotinamide phosphoribosyltransferase gene. J. Biol. Chem. 286: 14681-14690.
55. Paik, J. H., R. Kollipara, G. Chu, H. Ji, Y. Xiao, Z. Ding, L. Miao, Z. Tothova, J. W. Horner, D. R. Carrasco, et al. 2007. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell. 128: 309-323.
56. Zhao, J., J. J. Brault, A. Schild, P. Cao, M. Sandri, S. Schiaffino, S. H. Lecker, and A. L. Goldberg. 2007. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab. 6: 472-483.
57. Walker, A. K., R. L. Jacobs, J. L. Watts, V. Rottiers, K. Jiang, D. M. Finnegan, T. Shioda, M. Hansen, F. Yang, L. J. Niebergall, et al. 2011. A conserved SREBP-1/phosphatidylcholine feedback circuit regulates lipogenesis in metazoans. Cell. 147: 840-852.
58. Giandomenico, V., M. Simonsson, E. Gronroos, and J. Ericsson. 2003. Coactivator-dependent acetylation stabilizes members of the SREBP family of transcription factors. Mol. Cell. Biol. 23: 2587-2599.
59. Horton, J. D., N. A. Shah, J. A. Warrington, N. N. Anderson, S. W. Park, M. S. Brown, and J. L. Goldstein. 2003. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. USA. 100: 12027-12032.
60. Sato, R., J. Inoue, Y. Kawabe, T. Kodama, T. Takano, and M. Maeda. 1996. Sterol-dependent transcriptional regulation of sterol regulatory element-binding protein-2. J. Biol. Chem. 271: 26461-26464.
61. Vaquero, A., M. Scher, D. Lee, H. Erdjument-Bromage, P. Tempst, and D. Reinberg. 2004. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol. Cell. 16: 93-105.
62. Kamagate, A., and H. H. Dong. 2008. FoxO1 integrates insulin signaling to VLDL production. Cell Cycle. 7: 3162-3170.
63. Matsumoto, M., A. Pocai, L. Rossetti, R. A. Depinho, and D. Accili. 2007. Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell Metab. 6: 208-216.
64. Anselmi, C. V., A. Malovini, R. Roncarati, V. Novelli, F. Villa, G. Condorelli, R. Bellazzi, and A. A. Puca. 2009. Association of the FOXO3A locus with extreme longevity in a southern Italian centenarian study. Rejuvenation Res. 12: 95-104.
65. Flachsbart, F., A. Caliebe, R. Kleindorp, H. Blanche, H. von Eller- Eberstein, S. Nikolaus, S. Schreiber, and A. Nebel. 2009. Association of FOXO3A variation with human longevity confirmed in German centenarians. Proc. Natl. Acad. Sci. USA. 106: 2700-2705.
66. Willcox, B. J., T. A. Donlon, Q. He, R. Chen, J. S. Grove, K. Yano, K. H. Masaki, D. C. Willcox, B. Rodriguez, and J. D. Curb. 2008. FOXO3A genotype is strongly associated with human longevity. Proc. Natl. Acad. Sci. USA. 105: 13987-13992.
67. Soerensen, M., S. Dato, K. Christensen, M. McGue, T. Stevnsner, V. A. Bohr, and L. Christiansen. 2010. Replication of an association of variation in the FOXO3A gene with human longevity using both case-control and longitudinal data. Aging Cell. 9: 1010-1017.
68. Zeng, Y., L. Cheng, H. Chen, H. Cao, E. R. Hauser, Y. Liu, Z. Xiao, Q. Tan, X. L. Tian, and J. W. Vaupel. 2010. Effects of FOXO genotypes on longevity: a biodemographic analysis. J. Gerontol. A Biol. Sci. Med. Sci. 65: 1285-1299.
69. Suzuki, R., K. Lee, E. Jing, S. B. Biddinger, J. G. McDonald, T. J. Montine, S. Craft, and C. R. Kahn. 2010. Diabetes and insulin in regulation of brain cholesterol metabolism. Cell Metab. 12: 567-579. Kidney Diseases Kidney Diseases